Safety, Tolerability, and Pharmacokinetics of 3 g of Ceftolozane/Tazobactam in Healthy Adults: A Randomized, Placebo‐Controlled, Multiple‐Dose Study
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.429
Abstract: Ceftolozane/tazobactam is an antibacterial approved at 1.5 g (1g/0.5 g) every 8 hours (q8h); higher doses may provide additional benefits in difficult‐to‐treat infections. We conducted a phase I trial in healthy adults evaluating safety, tolerability,… read more here.
Keywords: day; healthy adults; ceftolozane tazobactam; safety tolerability ... See more keywords
Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.1733
Abstract: Ceftolozane/tazobactam (C/T) is a combination of a novel cephalosporin with tazobactam, recently approved for the treatment of hospital‐acquired and ventilator‐associated pneumonia. The plasma pharmacokinetics (PK) of a 3‐g dose of C/T (2 g ceftolozane and… read more here.
Keywords: plasma; ceftolozane; ceftolozane tazobactam; population ... See more keywords
Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia and End‐Stage Renal Disease Receiving Intermittent Hemodialysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.2149
Abstract: ASPECT‐NP, a phase 3 trial of ceftolozane/tazobactam in hospital‐acquired/ventilator‐associated bacterial pneumonia (HABP/VABP), excluded patients with end‐stage renal disease (ESRD). A modeling/simulation approach was undertaken to inform optimal dosing in this population, using previously developed ceftolozane… read more here.
Keywords: ceftolozane tazobactam; ceftolozane; acquired ventilator; hospital acquired ... See more keywords
Time–Kill Analysis of Ceftolozane/Tazobactam Efficacy Against Mucoid Pseudomonas aeruginosa Strains from Cystic Fibrosis Patients
Sign Up to like & getrecommendations! Published in 2017 at "Infectious Diseases and Therapy"
DOI: 10.1007/s40121-017-0176-8
Abstract: IntroductionMucoid Pseudomonas aeruginosa (MP) strains in cystic fibrosis (CF) patients are thought to initiate the chronic infection stage of CF and are associated with pulmonary function decline.ObjectivesThe purpose of this study was to assess the… read more here.
Keywords: tazobactam; kill analysis; ceftolozane tazobactam; time kill ... See more keywords
Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial
Sign Up to like & getrecommendations! Published in 2020 at "Infectious Diseases and Therapy"
DOI: 10.1007/s40121-020-00343-0
Abstract: Hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP) are associated with significant healthcare resource utilization (HCRU). This a priori, exploratory, secondary analysis from the ASPECT-NP clinical trial evaluated resource utilization among patients with ventilated HABP… read more here.
Keywords: resource utilization; ceftolozane tazobactam;
Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens.
Sign Up to like & getrecommendations! Published in 2020 at "Diagnostic microbiology and infectious disease"
DOI: 10.1016/j.diagmicrobio.2020.115101
Abstract: Ceftolozane-tazobactam is an antipseudomonal cephalosporin combined with a β-lactamase inhibitor. Ceftolozane-tazobactam has been approved for treatment of complicated urinary tract infections and acute pyelonephritis, for complicated intra-abdominal infections (with metronidazole) in adults, and for hospital-acquired… read more here.
Keywords: ceftolozane; gram negative; infections caused; ceftolozane tazobactam ... See more keywords
Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes.
Sign Up to like & getrecommendations! Published in 2018 at "International journal of antimicrobial agents"
DOI: 10.1016/j.ijantimicag.2017.11.003
Abstract: Infections due to multidrug-resistant bacteria (MDR) are currently a clinical challenge, mainly in elderly patients. The antimicrobial spectrum, safety and efficacy of ceftolozane/tazobactam (C/T) make it an attractive option for the treatment of MDR bacterial… read more here.
Keywords: skin soft; soft tissue; infections due; due extensively ... See more keywords
Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Sign Up to like & getrecommendations! Published in 2019 at "International journal of antimicrobial agents"
DOI: 10.1016/j.ijantimicag.2019.01.010
Abstract: OBJECTIVES Ceftolozane/tazobactam is a potential tool for infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa (P. aeruginosa), but its efficacy against some difficult-to-treat infections has not been well defined. METHODS Using an in vitro pharmacodynamic biofilm… read more here.
Keywords: tazobactam; combination; colistin; ceftolozane tazobactam ... See more keywords
The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and urinary tract infections-A meta-analysis of randomized controlled trials.
Sign Up to like & getrecommendations! Published in 2019 at "International journal of antimicrobial agents"
DOI: 10.1016/j.ijantimicag.2019.11.015
Abstract: OBJECTS This study aims to assess the clinical efficacy and safety of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infection (cIAI) and complicated urinary tract infection (cUTI) in adult patients through meta-analysis. METHODS PubMed, Embase,… read more here.
Keywords: tazobactam; tazobactam treatment; ceftolozane tazobactam; rate ... See more keywords
Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance.
Sign Up to like & getrecommendations! Published in 2021 at "International journal of antimicrobial agents"
DOI: 10.1016/j.ijantimicag.2021.106299
Abstract: OBJECTIVE To determine whether established ceftolozane/tazobactam (C/T) dosing is adequate among patients with augmented renal clearance (ARC) and bacterial infection. METHODS ARC (creatinine clearance [CrCl] ≥130 mL/min) was confirmed by directly measured CrCl in 11… read more here.
Keywords: ceftolozane tazobactam; renal clearance; clearance; patients augmented ... See more keywords
Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of global antimicrobial resistance"
DOI: 10.1016/j.jgar.2017.02.012
Abstract: Ceftolozane/tazobactam (C/T) is a novel β-lactam/β-lactamase inhibitor combination antibiotic approved by the US Food and Drug Administration for the treatment of complicated intra-abdominal and urinary tract infections due to Gram-negative bacteria, particularly extended-spectrum β-lactamase-producing Enterobacteriaceae… read more here.
Keywords: aeruginosa skin; skin soft; pseudomonas aeruginosa; soft tissue ... See more keywords